CD80 and glomerular disorder: In addition, the therapeutic effects of abatacept, a CTLA4-immunoglobulin fusion protein (CTLA4-Ig) which blocks the interaction between B7-1 (APC) and CD28 (T cell), are still in uncertainty in glomerular diseases [25].